We use cryo-electron microscopy and complementary structural biology techniques to determine high-resolution structures of membrane proteins and protein complexes relevant to human disease.

Wnt proteins are essential for many cell processes, including differentiation and migration. Porcupine (PORCN) is a transmembrane protein that modifies all Wnts with a fatty molecule, which is crucial for Wnt secretion and activity. Because of this, PORCN inhibitors show potential for treating various types of human cancers. Using cryo-EM, we achieved the highest resolution PORCN structure (2.5 Å) with a small molecule inhibitor. This project will expand upon our PORCN work and employ cryo-EM to determine the PORCN-Wnt complex structure, aiming to understand Wnt modification by PORCN at the molecular level.
Wnt signaling is initiated by Wnt proteins when they interact with their receptors, Frizzled, and co-receptors. Although this step is crucial for understanding Wnt signaling biology and developing new therapies, the molecular details remain elusive. Existing structural information on individual steps is incomplete, and the full picture is yet to be uncovered. This project aims to employ structural biology and complementary techniques to gain insights into how Wnt binding leads to Frizzled activation and signal transmission into the cell.
Wnt proteins play a vital role in various cell processes, including differentiation and migration. As lipophilic molecules, Wnts require carrier proteins to maintain solubility outside cells. The exact interaction mechanism between Wnts and these carrier proteins remains unknown. This project will employ cryo-electron microscopy, x-ray crystallography, and complementary techniques to investigate Wnt complexes with extracellular proteins, such as afamin, serum albumin, and Norrin, to enhance understanding of their interactions and regulatory functions.

The enzyme 12-Lipoxygenase (12-LOX) is a promising drug target for preventing platelet activation and thrombosis. ML355, a 12-LOX inhibitor, has shown potential in treating heparin-induced thrombocytopenia. In collaboration with the Thal, Holman, and Holinstat laboratories, we were the first to determine high-resolution structures of human 12-LOX, including structures with the clinically relevant inhibitor ML355 and an endogenous acyl-coenzyme A. This project aims to build upon our structural studies to further understand 12-LOX biology, including its oligomeric states, catalysis, and membrane binding, and to gain insights into a new generation of 12-LOX inhibitors.